EIP Pharma announced on October 6 that a phase 2 study in patients with mild-to-moderate Lewy body dementia (LBD) demonstrated an improvement in cognition as assessed by the Neuropsychological Test Battery (NTB). In the double-blind placebo-controlled study, patients receiving neflamapimod three times daily demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily. In addition, statistically significant improvements or trends were evident on multiple secondary goals.
“The data from the trial of neflamapimod in dementia with Lewy bodies are very encouraging,” said Jeffrey L. Cummings, MD, ScD, Joy Chambers-Grundy Professor of Brain Science and Director of the Chambers-Grundy Center for Transformative Science at the UNLV School of Integrated Health Sciences. “Not only was the prespecified primary outcome met for the three times daily dose arm but supportive trends were observed in several of the secondary outcomes, setting the stage for more extensive testing. There are no approved treatments for DLB, the second most common cause of neurodegenerative dementia, and there is an urgent need to find therapies for this and related disorders such as Alzheimer’s disease.”
As a Lewy Body Dementia Association (LBDA) Center of Excellence, UNC Neurology served as one of the phase 2 study sites. Dr. Daniel Kaufer and Dr. Gwenn Garden were principal investigators (PI) of the trial. UNC Neurology is expected to be included as a study site for the planned phase 3 clinical trial. Dr. Andrea Bozoki, Division Chief of Behavioral Neurology, will serve as the PI.
Source: Read Full Article